Cystein-isopropylester | 94359-76-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Cystein-isopropylester
• 英文别名: Propan-2-yl 2-amino-3-sulfanylpropanoate
• CAS: 94359-76-9
• 化学式: C₆H₁₃NO₂S
• 分子量: 163.241
• InChiKey: HXHFZINLHDNRTP-UHFFFAOYSA-N

物化性质

• 沸点：
  214.7±30.0 °C(Predicted)
• 密度：
  1.091±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  53.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• THERAPEUTIC USES OF GLUTATHIONE MIMICS
  申请人：Gaillard Elizabeth R.

  公开号：US20090005349A1

  公开（公告）日：2009-01-01

  A prodrug having antioxidant activity, including a phosphorylated compound having a thiol group. A method of treating oxidative stress by administering a prodrug of a phosphorylated compound including a thiol group, removing a phosphate group of the prodrug, and treating oxidative stress. A method of increasing bioavailability of a thiol compound by creating a prodrug by phosphorylating a thiol compound, administering the prodrug, preventing first pass metabolism of the prodrug, removing a phosphate group from the prodrug, and providing active drug to a site in need of therapy from oxidative stress. A method of preventing radiation damage to healthy tissue by administering a prodrug comprising a phosphorylated compound including a thiol group, removing a phosphate group of the prodrug to provide active drug, and preventing radiation damage to healthy tissue.

  一种具有抗氧化活性的前药，包括具有巯基的磷酸化合物。一种通过给予具有巯基的磷酸化合物的前药，去除前药的磷酸基，治疗氧化应激的方法。一种通过磷酸化巯基化合物创建前药，给予前药，防止前药的首过代谢，去除前药的磷酸基，并向需要治疗氧化应激的部位提供活性药物来增加巯基化合物的生物利用度的方法。一种通过给予包括巯基的磷酸化合物的前药，去除前药的磷酸基以提供活性药物，并防止对健康组织的辐射损伤的方法。
• [EN] COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT DE TROUBLES OCULAIRES
  申请人：AZURA OPHTHALMICS LTD

  公开号：WO2022084747A1

  公开（公告）日：2022-04-28

  Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti- inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

  本文描述了一种治疗或预防眼表面疾病的组合物和方法，包括睑腺功能障碍、睑缘炎、干眼病和其他前表面炎症和/或感染性眼疾。所述的组合物和方法包括角质溶解偶联物，其表现出角质溶解活性，以及抗炎或其他理想活性。将所述组合物局部给药于眼睑边缘或周围区域，可为患有眼表面疾病的患者提供治疗益处。
• Bioavailability and improved delivery of acidic pharmaceutical drugs
  申请人：——

  公开号：US20040220264A1

  公开（公告）日：2004-11-04

  Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition. The compositions include a molecular complex formed between an acidic pharmaceutical drug and at least one functional substance. The compositions provide improved bioavailability and improved delivery of the drug into the cutaneous tissues.

  本发明的实施方案涉及一种组合物、制作该组合物的工艺以及该组合物的用途。 组合物包括酸性药物和至少一种功能物质之间形成的分子复合物。 该组合物提高了药物的生物利用度，并改善了药物向皮肤组织的输送。
• TOXIC AGENT PROTECTIVE COMPOUNDS, COMPOSITIONS AND METHOD
  申请人：The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and

  公开号：EP0546063A1

  公开（公告）日：1993-06-16
• IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS
  申请人：Yu, Ruey J., Dr.

  公开号：EP1603549A2

  公开（公告）日：2005-12-14